vs
Side-by-side financial comparison of MEDICAL PROPERTIES TRUST INC (MPW) and Protagonist Therapeutics, Inc (PTGX). Click either name above to swap in a different company.
MEDICAL PROPERTIES TRUST INC is the larger business by last-quarter revenue ($270.3M vs $170.6M, roughly 1.6× Protagonist Therapeutics, Inc). Protagonist Therapeutics, Inc runs the higher net margin — 77.2% vs 6.5%, a 70.7% gap on every dollar of revenue. On growth, Protagonist Therapeutics, Inc posted the faster year-over-year revenue change (184.4% vs 16.6%).
Medical Properties Trust, Inc. (MPT) is an international real estate investment trust (REIT) based in Birmingham, Alabama that purchases and invests in healthcare facilities and for-profit healthcare holding companies, primarily in the United States and Europe. Their property acquisitions often come in the form of sale-leaseback agreements, in which the original property owner sells the property to MPT and becomes their tenant. MPT's tenants are generally subject to long-term triple net lease...
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.
MPW vs PTGX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $270.3M | $170.6M |
| Net Profit | $17.6M | $131.7M |
| Gross Margin | 95.8% | — |
| Operating Margin | 9.7% | 74.3% |
| Net Margin | 6.5% | 77.2% |
| Revenue YoY | 16.6% | 184.4% |
| Net Profit YoY | 104.3% | 381.7% |
| EPS (diluted) | $0.03 | $2.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $270.3M | — | ||
| Q3 25 | $237.5M | — | ||
| Q2 25 | $240.4M | — | ||
| Q1 25 | $223.8M | — | ||
| Q4 24 | $231.8M | $170.6M | ||
| Q3 24 | $225.8M | — | ||
| Q2 24 | $266.6M | — | ||
| Q1 24 | $271.3M | $255.0M |
| Q4 25 | $17.6M | — | ||
| Q3 25 | $-77.7M | — | ||
| Q2 25 | $-98.4M | — | ||
| Q1 25 | $-118.3M | — | ||
| Q4 24 | $-412.3M | $131.7M | ||
| Q3 24 | $-801.2M | — | ||
| Q2 24 | $-320.6M | — | ||
| Q1 24 | $-875.6M | $207.3M |
| Q4 25 | 95.8% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 91.8% | — | ||
| Q1 25 | 63.6% | — | ||
| Q4 24 | 90.9% | — | ||
| Q3 24 | 96.5% | — | ||
| Q2 24 | 98.4% | — | ||
| Q1 24 | 84.9% | — |
| Q4 25 | 9.7% | — | ||
| Q3 25 | -28.0% | — | ||
| Q2 25 | -36.7% | — | ||
| Q1 25 | -48.5% | — | ||
| Q4 24 | -173.7% | 74.3% | ||
| Q3 24 | -350.7% | — | ||
| Q2 24 | -114.5% | — | ||
| Q1 24 | -318.6% | 80.9% |
| Q4 25 | 6.5% | — | ||
| Q3 25 | -32.7% | — | ||
| Q2 25 | -40.9% | — | ||
| Q1 25 | -52.8% | — | ||
| Q4 24 | -177.8% | 77.2% | ||
| Q3 24 | -354.8% | — | ||
| Q2 24 | -120.3% | — | ||
| Q1 24 | -322.7% | 81.3% |
| Q4 25 | $0.03 | — | ||
| Q3 25 | $-0.13 | — | ||
| Q2 25 | $-0.16 | — | ||
| Q1 25 | $-0.20 | — | ||
| Q4 24 | $-0.68 | $2.01 | ||
| Q3 24 | $-1.34 | — | ||
| Q2 24 | $-0.54 | — | ||
| Q1 24 | $-1.46 | $3.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $540.9M | $418.9M |
| Total DebtLower is stronger | $9.7B | — |
| Stockholders' EquityBook value | $4.6B | $675.3M |
| Total Assets | $15.0B | $744.7M |
| Debt / EquityLower = less leverage | 2.11× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $540.9M | — | ||
| Q3 25 | $396.6M | — | ||
| Q2 25 | $509.8M | — | ||
| Q1 25 | $673.5M | — | ||
| Q4 24 | $332.3M | $418.9M | ||
| Q3 24 | $275.6M | — | ||
| Q2 24 | $606.5M | — | ||
| Q1 24 | $224.3M | $322.6M |
| Q4 25 | $9.7B | — | ||
| Q3 25 | $9.6B | — | ||
| Q2 25 | $9.6B | — | ||
| Q1 25 | $9.5B | — | ||
| Q4 24 | $8.8B | — | ||
| Q3 24 | $9.2B | — | ||
| Q2 24 | $9.4B | — | ||
| Q1 24 | $10.1B | — |
| Q4 25 | $4.6B | — | ||
| Q3 25 | $4.7B | — | ||
| Q2 25 | $4.8B | — | ||
| Q1 25 | $4.8B | — | ||
| Q4 24 | $4.8B | $675.3M | ||
| Q3 24 | $5.4B | — | ||
| Q2 24 | $6.2B | — | ||
| Q1 24 | $6.7B | $560.4M |
| Q4 25 | $15.0B | — | ||
| Q3 25 | $14.9B | — | ||
| Q2 25 | $15.2B | — | ||
| Q1 25 | $14.9B | — | ||
| Q4 24 | $14.3B | $744.7M | ||
| Q3 24 | $15.2B | — | ||
| Q2 24 | $16.2B | — | ||
| Q1 24 | $17.3B | $629.3M |
| Q4 25 | 2.11× | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | 2.00× | — | ||
| Q1 25 | 1.99× | — | ||
| Q4 24 | 1.83× | — | ||
| Q3 24 | 1.69× | — | ||
| Q2 24 | 1.51× | — | ||
| Q1 24 | 1.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $230.8M | $184.2M |
| Free Cash FlowOCF − Capex | — | $182.8M |
| FCF MarginFCF / Revenue | — | 107.1% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | 13.11× | 1.40× |
| TTM Free Cash FlowTrailing 4 quarters | — | $101.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.8M | — | ||
| Q3 25 | $18.6M | — | ||
| Q2 25 | $51.7M | — | ||
| Q1 25 | $384.0K | — | ||
| Q4 24 | $245.5M | $184.2M | ||
| Q3 24 | $59.2M | — | ||
| Q2 24 | $35.3M | — | ||
| Q1 24 | $74.3M | $-27.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $182.8M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-27.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 107.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -10.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.1% |
| Q4 25 | 13.11× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
